LISTED Philab Holdings Corp. is planning to acquire 67-percent equity in Sydenham Laboratories, Inc., subject to the approval of the Philippine Stock Exchange and the Securities and Exchange Commission.
Sydenham is a manufacturer of hormone-based drugs and specializes in oral drug preparation in dosage forms such as tablet, syrup, capsule, and powder for suspension.
Already have an active account? Log in here.
Continue reading with one of these options:
Continue reading with one of these options:
Premium + Digital Edition
Ad-free access
P 80 per month
(billed annually at P 960)
- Unlimited ad-free access to website articles
- Limited offer: Subscribe today and get digital edition access for free (accessible with up to 3 devices)
TRY FREE FOR 14 DAYS
See details
See details
If you have an active account, log in
here
.